Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by NKGen Biotech

NKGen Biotech, Inc. to Transition from the Nasdaq Global Market to OTC Markets; Reverse Stock Split will not be Implemented
From NKGen Biotech
Via GlobeNewswire
Tickers NKGN
NKGen Biotech Announces Administration of First Dose of Troculeucel to Stroke Patient Under FDA-Cleared Compassionate Use Program
From NKGen Biotech
Via GlobeNewswire
Tickers NKGN
NKGen Biotech Announces Administration of First Dose of Troculeucel to Frontotemporal Dementia Patient Under FDA-Cleared Compassionate Use Program
From NKGen Biotech
Via GlobeNewswire
Tickers NKGN
NKGen Appoints Dr. Anita Fletcher as National Principal Investigator for Phase 2a Troculeucel Trial Evaluating Moderate Alzheimer’s Disease with AdventHealth Orlando as First East Coast Site
From NKGen Biotech
Via GlobeNewswire
Tickers NKGN
NKGen Biotech Announces Publication of Phase 1 Troculeucel Clinical Trial Results for the Treatment of Alzheimer’s Disease
From NKGen Biotech
Via GlobeNewswire
Tickers NKGN
NKGen Biotech Receives U.S. FDA Fast Track Designation for Troculeucel for the Treatment of Moderate Alzheimer’s Disease
From NKGen Biotech
Via GlobeNewswire
Tickers NKGN
NKGen Biotech Presents Phase 1/2a Troculeucel Data in Alzheimer’s Disease at the 17th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference
From NKGen Biotech
Via GlobeNewswire
Tickers NKGN
NKGen Biotech Announces Upcoming Presentation at the 16th World Stroke Congress (WSC 2024)
From NKGen Biotech
Via GlobeNewswire
Tickers NKGN
NKGen Biotech Announces Poster Presentations at the 17th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference
From NKGen Biotech
Via GlobeNewswire
Tickers NKGN
NKGen Biotech’s Positive Phase 1 Clinical Data in Moderate Alzheimer’s Disease Advances Troculeucel into Phase 2 with First Patient Dosed in Phase 1/2a Trial
From NKGen Biotech
Via GlobeNewswire
Tickers NKGN
NKGen Biotech to Present at the H.C. Wainwright 26th Annual Global Investment Conference
From NKGen Biotech
Via GlobeNewswire
Tickers NKGN
NKGen Biotech Presents New Positive SNK01 Biomarker Data at the 2024 Alzheimer’s Association International Conference
From NKGen Biotech
Via GlobeNewswire
Tickers NKGN
NKGen Biotech to Present New Positive SNK01 Clinical Trial Biomarker Data at the 2024 Alzheimer’s Association International Conference
From NKGen Biotech
Via GlobeNewswire
Tickers NKGN
NKGen Biotech Appoints Dr. Marco Gottardis to its Board of Directors
From NKGen Biotech
Via GlobeNewswire
Tickers JNJ NKGN
NKGen Biotech Presents Updated Phase 1 Data on SNK02 Allogeneic NK Cell Therapy for Solid Tumors at the 6th Annual Allogeneic Cell Therapies Summit 2024
From NKGen Biotech
Via GlobeNewswire
Tickers NKGN
NKGen Biotech to Present at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting
From NKGen Biotech
Via GlobeNewswire
NKGen Biotech, Inc. to Become Publicly Traded Company via Business Combination with Graf Acquisition Corp. IV
From NKGen Biotech
Via GlobeNewswire
Tickers GFOR
NKGen Biotech Announces Formation of Scientific Advisory Board to Drive its Pipeline Strategy for Natural Killer Cell Therapies Targeting Neurodegenerative Diseases
From NKGen Biotech
Via GlobeNewswire
NKGen Biotech Appoints Paul Y. Song, MD as Chief Executive Officer
From NKGen Biotech
Via GlobeNewswire
NKGen Biotech Announces Collaboration with the Parkinson’s Foundation to Bring Its Novel Natural Killer Cell Therapy to the Clinic for Advanced Parkinson’s Disease
From NKGen Biotech
Via GlobeNewswire
NKGen Biotech Receives IND Clearance from FDA for SNK02 Allogeneic Natural Killer Cell Therapy for Solid Tumors
From NKGen Biotech
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.